公开(公告)号：US20240108595A1

公开(公告)日：2024-04-04

申请号：US18464725

申请日：2023-09-11

申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  UNIVERSITY OF PITTSBURGH MEDICAL CENTER

发明人： Robert A. SWEET ,  Brandon C. MCKINNEY ,  LiRong WANG ,  Matthew Luke MACDONALD ,  Peihao FAN ,  Joshua Michael KRIVINKO

IPC分类号： A61K31/221 ,  A61K31/42 ,  A61K31/436 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5685 ,  A61K31/737 ,  A61P25/28

CPC分类号： A61K31/221 ,  A61K31/42 ,  A61K31/436 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5685 ,  A61K31/737 ,  A61P25/28

摘要： Described herein are methods of treating, preventing, or reducing dendritic spine density loss in a subject, the method comprising administering a compound selected from: metformin, pentosan polysulfate, amlexanox, leflunomide, prasterone, glutathione disulfide, pazopanib, bosutinib, dabrafenib, baricitinib, or a pharmaceutically acceptable salt, prodrug, or derivative thereof; or any combination thereof; or compositions described herein.

公开(公告)号：US12115079B2

公开(公告)日：2024-10-15

申请号：US17600259

申请日：2020-04-15

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Patrick Peter Bosch

IPC分类号： A61F2/36 ,  A61F2/32 ,  A61F2/30

CPC分类号： A61F2/3609 ,  A61F2/32 ,  A61F2002/30062 ,  A61F2002/30462 ,  A61F2002/30566 ,  A61F2002/3233

摘要： Hip tethering devices comprise a femoral implant including a housing that anchors the femoral implant to the femur, at least one spring, and a slider, such that the slider can move relative to the housing via compression and expansion of the at least one spring. A tether has a first end that anchors to the acetabulum, the tether passes through the femoral head, and a second end couples to the slider of the femoral implant, such that the tether spans across the patient's hip joint and relative motion between the slider and the housing allows a limited degree of separation of the femoral head from the acetabulum, while the at least one spring applies a variable tension load to the tether that resists separation of the femoral head from the acetabulum.

公开(公告)号：US20240336663A1

公开(公告)日：2024-10-10

申请号：US18579170

申请日：2022-07-15

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Samira KIANI ,  Tahere MOKHTARI

IPC分类号： C07K14/435 ,  A61K38/00 ,  A61K48/00 ,  A61P29/00 ,  C12N15/86

CPC分类号： C07K14/435 ,  A61K48/005 ,  A61P29/00 ,  C12N15/86 ,  A61K38/00 ,  C07K2319/81 ,  C12N2750/14143

摘要： A non-naturally occurring zinc finger protein, wherein the zinc finger protein specifically binds to the promoter region of the Myd88 gene, is provided, as well as related polynucleotides, vectors, cells, and pharmaceutical compositions. In some aspects, the zinc finger protein comprises one or more repressors. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier and: (A) one or more RNA interference (RNAi) agents targeting the Myd88 gene, or related polynucleotides, vectors, or cells: (B) a target antigen or a polynucleotide encoding the target antigen; and (C) a gene therapy are also provided. Methods for ameliorating inflammation and/or immune response in a subject using the RNAi agents, zinc finger protein, polynucleotides, vectors, cells, and pharmaceutical compositions also are provided.

公开(公告)号：US20240335408A1

公开(公告)日：2024-10-10

申请号：US18619902

申请日：2024-03-28

申请人： University of Pittsburgh - of the Commonwealth System of Higher Education

发明人： Anthony J. Kanai ,  Irina Zabbarova ,  Youko Ikeda

IPC分类号： A61K31/197 ,  A61K31/192 ,  A61K31/47 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

CPC分类号： A61K31/197 ,  A61K31/192 ,  A61K31/47 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

摘要： Provided herein are methods of treating cancer and fibrosis in a patient. The cancer may be prostate cancer. The fibrosis may be cystitis arising from a cancer therapy, such as from treatment of prostate cancer. The methods involve activation of senescent cells, such as senescent cancer cells with a soluble guanylate cyclase activator. The treatment with the soluble guanylate cyclase activator may be a primary therapy or an adjuvant therapy to a primary cancer therapy such as a chemotherapy or radiation therapy. The treatment may be administered after completion of a primary cancer therapy.

公开(公告)号：US20240335372A1

公开(公告)日：2024-10-10

申请号：US18294226

申请日：2022-08-02

申请人： University of Pittsburgh-Of the Commonwealth System of Higher Education

发明人： Lisa Cencia Rohan ,  Prithivirajan Durairajan ,  Sravan Kumar Patel

IPC分类号： A61K9/00 ,  A61K9/70 ,  A61P31/12

CPC分类号： A61K9/0036 ,  A61K9/7007 ,  A61P31/12

摘要： Provided herein are stable, bioerodible films containing active ingredients, such as antimicrobial composition, antiviral compositions, antiretroviral compositions, and/or contraceptive compositions for intravaginal placement to provide prophylaxis against viral infections and contraception.

公开(公告)号：US12110316B2

公开(公告)日：2024-10-08

申请号：US17287480

申请日：2019-10-18

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Alan H. Wells

IPC分类号： C07K14/52 ,  C12N9/64 ,  A61K38/00

CPC分类号： C07K14/522 ,  C12N9/6491 ,  A61K38/00

摘要： Recombinant C-X-C motif chemokine ligand (CXCL) peptides modified to introduce a cleavage site for a protease, such as a protease activated during an inflammatory response, are described. The CXCL peptides have the capacity to activate CXCR3 until being cleaved by the protease. Proteolytic cleavage of the CXCL peptide minimizes the pro-inflammatory response and inhibits the development of fibrosis.

公开(公告)号：US20240325537A1

公开(公告)日：2024-10-03

申请号：US18580954

申请日：2022-07-19

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Greg M. Delgoffe ,  Ronal Peralta

IPC分类号： A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/113

CPC分类号： A61K39/464412 ,  A61K39/4611 ,  A61K39/4644 ,  A61K39/464404 ,  A61K39/464406 ,  A61K39/464417 ,  A61K39/464424 ,  A61K39/464466 ,  A61K39/464468 ,  A61K39/46447 ,  A61K39/464474 ,  A61K39/464482 ,  A61K39/464494 ,  A61K45/06 ,  A61P35/00 ,  C07K14/7051 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2501/2302 ,  C12N2510/00

摘要： The present disclosure provides compositions, including modified peripheral blood mononuclear cells (PBMCs) with reduced expression of Slc16a11 and/or reduced activity of MCT11. Also provided are siRNAs and gRNAs targeting Slc16a11. Methods of using the disclosed compositions in the treatment of cancer are also provided.

公开(公告)号：US20240307493A1

公开(公告)日：2024-09-19

申请号：US18738964

申请日：2024-06-10

申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Binfeng Lu ,  Runzi Sun

IPC分类号： A61K38/20 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K38/20 ,  A61K39/3955 ,  A61P35/00

摘要： The present disclosure relates to the methods of preventing and/or treating cancer including administering IL33 and anti-AREG antibodies or fragments thereof to a subject in need thereof. The present disclosure further provides compositions and kits for performing such methods.

公开(公告)号：US20240304828A1

公开(公告)日：2024-09-12

申请号：US18654149

申请日：2024-05-03

申请人： UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Prashant N. Kumta ,  Prasad P. Patel ,  Moni K. Datta ,  Oleg Velikokhatnyi ,  Prashanth J. Hanumantha ,  Ramalinga Kuruba ,  Shrinath Ghadge

IPC分类号： H01M4/90 ,  B01J27/135 ,  B82Y30/00 ,  H01M4/88 ,  H01M8/08 ,  H01M8/1018 ,  H01M8/1233

CPC分类号： H01M4/9016 ,  H01M4/881 ,  H01M4/8825 ,  H01M8/08 ,  H01M8/1018 ,  H01M8/1233 ,  B01J27/135 ,  B82Y30/00 ,  Y02E60/50

摘要： The invention provides noble metal-free electro-catalyst compositions for use in acidic media, e.g., acidic electrolyte. The noble metal-free electro-catalyst compositions include non-noble metal absent of noble metal. The non-noble metal is non-noble metal oxide, and typically in the form of any configuration of a solid or hollow nano-material, e.g., nano-particles, a nanocrystalline thin film, nanorods, nanoshells, nanoflakes, nanotubes, nanoplates, nanospheres and nanowhiskers or combinations of myriad nanoscale architecture embodiments. Optionally, the noble metal-free electro-catalyst compositions include dopant, such as, but not limited to halogen. Acidic media includes oxygen reduction reaction (ORR) in proton exchange membrane (PEM) fuel cells, and direct methanol fuel cells and oxygen evolution reaction (OER) in PEM-based water electrolysis and metal air batteries, and hydrogen generation from solar energy and electricity-driven water splitting.

公开(公告)号：US20240299599A1

公开(公告)日：2024-09-12

申请号：US18515076

申请日：2023-11-20

申请人： University of Pittsburgh - of the Commonwealth System of Higher Education

发明人： Dexing ZENG ,  Lingyi SUN ,  Yongkang GAI

IPC分类号： A61K51/08 ,  A61K9/51 ,  A61K47/68 ,  A61K51/10 ,  C07D255/02 ,  C07D257/02 ,  C07K7/06 ,  C07K7/64 ,  C07K16/30 ,  G01N33/50 ,  G01N33/60

CPC分类号： A61K51/082 ,  A61K9/51 ,  A61K47/6893 ,  A61K51/1027 ,  C07D255/02 ,  C07D257/02 ,  C07K7/06 ,  C07K7/64 ,  C07K16/30 ,  G01N33/5008 ,  G01N33/60 ,  C07K2319/00

摘要： The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.